Mixed preparations of fibroblast and immune interferons interacted with cells synergistically to cause the development of a much greater level of protection than expected on the basis of their separate activities. This increased level of protection was 5-to 20-fold greater than expected on the basis of a simple additive effect of the interferons. The potentiating factor copurified with both fibroblast interferon and immune interferon as they were partially purified. The potentiation was not an artifact of a more rapid development of immune interferon-induced antiviral resistance in the presence of fibroblast interferon. The results were consistent with the hypothesis that fibroblast and immune interferons mutually potentiate each other, thus supporting the supposition that they have different modes of action.
There is strong evidence that the interferon system has three important functions in the host: an antiviral function, an antitumor function, and an immunoregulatory function (1) . An understanding of these functions of interferon is complicated by the fact that both the human interferon system and the mouse interferon system are complex and can each be provisionally subdivided into at least three antigenically distinct types, which are named for their cellular sources (3, 7-9, 12, 20) . Fibroblast and leukocyte interferons are usually induced by viruses or synthetic polyribonucleotides, whereas immune interferons are usually induced in sensitized lymphocytes by a specific antigen or in unsensitized lymphocytes by T-cell mitogens (6, 11, 16, 18, 19) .
In this work, the interaction of two of these interferons was studied. Our observations suggest that when cell monolayers are treated with mixtures of fibroblast and immune interferons, a great enhancement or potentiation of antiviral protection occurs. The level of protection observed for such mixed preparations was 5-to 20-fold greater than expected on the basis of the separate activities of these interferons. Thus, this increased antiviral activity is not merely an additive effect of the interferons, but represents a synergistic amplification of interferon-mediated protection against virus infection. The potentiating factor(s) copurifies with the fibroblast and immune interferons.
MATERIALS AND METHODS
Cells and viruses. Mouse L cells (clone 929) were employed in all experiments and assays. Cells were routinely passaged every 2 to 3 days in sealed 32-ounce (946-ml) bottles and maintained in Eagle minimal essential medium (Hanks base; Grand Island Biological Co.) supplemented with 10% fetal calf serum (Flow Laboratories) at 37°C. For yield reduction experiments and plaque assays, cells were plated at 106 cells per dish on standard (Falcon Plastics) and Contur (Lux) 35-mm plastic petri dishes, respectively. They were maintained in Eagle minimal essential medium (Earle base; Grand Island Biological Co.) supplemented with 10% fetal calf serum at 37°C in a humidified, 4% CO2 atmosphere.
Mengovirus was employed for all experiments and assays. For yield reduction experiments, 10 plaqueforming units (PFU) per cell was incubated with L-cell monolayers for 45 min. After a double wash to remove unabsorbed virus, the cultures were incubated for 24 h before progeny virus was harvested and quantitated by plaque assay. For plaque assay experiments, after a 45-min absorption period, these monolayers were overlaid with a starch (Sigma Chemical Co.) overlay as previously described (5) . After 24 h of incubation, the monolayers were stained with 7 to 10 drops of a 0.2% (wt/vol) neutral red (Sigma) preparation, and plaques were counted 2 to 3 h later.
Interferon production and titration. Mouse C243 cells were used for the production of fibroblasttype interferon as previously described (14) . C243 cells were maintained in the same medium as described above for L cells. Monolayers were stimulated with Newcastle disease virus. The supernatant fluids were harvested at 24 h postinfection. 3- fold, whereas 26 U of fibroblast interferon reduced virus yield by 43-fold. More importantly, the level of protection observed when immune and fibroblast interferons were added in combination was 714-fold, much greater than predicted on the basis of their separate protective abilities. The virus yields were compared with a standard curve of virus yields generated concurrently for known amounts of fibroblast interferon in order to convert the observed virus yield to units of actual interferon activity. The virus Effect of partial purification of immune interferon on potentiation. Partially purified immune interferon was tested for its potentiating ability in order to determine whether the potentiation phenomenon was due to a factor separable from immune interferon. The immune interferon was purified as previously described (15) . Briefly, the immune interferon was purified 200-fold by differential ammonium sulfate precipitation and Ultrogel AcA 34 gel filtration chromatography. The potentiation capability of this partially purified immune interferon was compared with that of unpurified immune interferon. The results of a representative experiment are presented in Table 3 . Approximately equal amounts of unpurified and partially purified immune interferon (6 and 5 U, respectively) were found to potentiate 20 U of fibroblast interferon interferon, 200-fold-purified immune interferon from an Ultrogel filtration of immune interferon, fibroblast interferon, unpurified immune interferon plus fibroblast interferon in combination, and partially purified immune interferon plus fibroblast interferon in combination. The monolayers were challenged with mengovirus at a multiplicity of infection of 10 PFU/cell, and virus yields were harvested 24 h later.
b Mean ± standard deviation. 200 -fold-purified and unpurified immune interferon. Since the potentiating activity quantitatively copurified with the immune interferon, there is no evidence that a separate molecular entity present in the immune interferon preparation was responsible for the potentiation effect. However, since the purification was dependent on molecular weight differences in the proteins, more work is necessary to determine the relationship of potentiator and immune interferon.
Third, fibroblast interferon could cause potentiation by accelerating the kinetics of establishment of the immune interferon-induced antiviral state. Establishment of the antiviral state occurs more slowly in response to immune interferon than to fibroblast interferon treatment (2) . The possibility existed that the immune interferoninduced antiviral state developed more rapidly when the immune interferon was coincubated with the more rapidly acting fibroblast interferon. However, this was shown not to be the case. The protective effect of immune interferon when added alone did increase with time, but so did the protective and the potentiation effects when immune and fibroblast interferons were added together. Thus, fibroblast interferon did not potentiate immune interferon by speeding up the kinetics of establishment of the immune interferon-induced antiviral state.
Fourth, the two types of interferon could potentiate each other. Although there is no evidence to directly support this theory, the present inability to separate a potentiating factor from the two interferons causes this explanation to be the most attractive. This explanation suggests that the mechanisms by which fibroblast interferon and immune interferon block virus replication are distinct and that they can act synergistically.
Some immune interferon preparations have been shown to contain an inhibitor of interferon (W. R. Fleishmann, Jr., J. Georgiades, H. M. Johnson, F. Dianzani, and S. Baron, Bacteriol. Proc., p. 247, 1978) . The potentiation phenomenon was not an artifact of this inhibitor effect. The inhibitor was not produced by staphylococcal enterotoxin A-stimulated mouse spleen cells until day 3 of stimulation. The immune interferon preparations used in this study were harvested after 2 days of mitogen stimulation and thus contained no inhibitor activity.
A phenomenon related to potentiation occurs when cultured cells pretreated with a low level of interferon develop antiviral activity faster and to a greater level when subsequently exposed to a high level of the same interferon than they would if exposed initially only to a high level of interferon (priming) (4, 17) . The potentiation described in this paper appears to be different from priming, since (i) for potentiation the fibroblast and immune interferons were added simultaneously without the required pretreatment for the priming phenomenon, and (ii) potentiation required two different types of interferon, whereas priming occurs with two additions of the same interferon.
Although the potentiating factor has not yet been identified, the available evidence indicates that it copurified with the interferons. If the two types of interferons do potentiate each other, then these results suggest that the local production of multiple types of interferon may play a significant role in the activation of cells by interferon. Whatever the mechanism of potentiation, additional studies are necessary to define the role which the potentiation effect plays in influencing the progress of viral disease.
